1.Darby, S, McGale, P, Correa, Cet al. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta- analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet 2011; 378 (9804): 1707–1716.
2.Clarke, M, Collins, R, Darby, Set al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 366 (9503): 2087–2106.
3.Overgaard, M, Bentzen, S M, Christensen, J J, Madsen, E H. The value of the NSD formula in equation of acute and late radiation complications in normal tissue following 2 and 5 fractions per week in breast cancer patients treated with postmastectomy irradiation. Radiother Oncol 1987; 9 (1): 1–11.
4.Rothwell, R I, Kelly, S A, Joslin, C A. Radiation pneumonitis in patients treated for breast cancer. Radiother Oncol 1985; 4 (1): 9–14.
5.Marks, L B, Yu, X, Vujaskovic, Z, Small, W Jr, Folz, R, Anscher, MS. Radiation-induced lung injury. Semin Radiat Oncol 2003; 13 (3): 333–345.
6.Kahan, Z, Csenki, M, Varga, Zet al. The risk of early and late lung sequelae after conformal radiotherapy in breast cancer patients. Int J Radiat Oncol Biol Phys 2007; 68 (3): 673–681.
7.Hermann, T S J, Molls, M. Radiation Pneumopathy. Experimental and clinical data. In: Dunst J, Sauer R H (eds). Late Sequelae in Oncology. Berlin, Heidelberg, New York, 1995: 135–140.
8.Lind, P A, Wennberg, B, Gagliardi, G, Fornander, T. Pulmonary complications following different radiotherapy techniques for breast cancer, and the association to irradiated lung volume and dose. Breast Cancer Res Treat 2001; 68 (3): 199–210.
9.Marks, L B, Yorke, E D, Jackson, Aet al. Use of normal tissue complication probability models in the clinic. Int J Radiat Oncol Biol Phys 2010; 76 (suppl 3): S10–S19.
10.Bentzen, S M, Skoczylas, J Z, Overgaard, M, Overgaard, J. Radiotherapy-related lung fibrosis enhanced by tamoxifen. J Natl Cancer Inst 1996; 88 (13): 918–922.
11.Dorr, W, Bertmann, S, Herrmann, T. Radiation induced lung reactions in breast cancer therapy. Modulating factors and consequential effects. Strahlenther Onkol 2005; 181 (9): 567–573.
12.Lind, P A, Bylund, H, Wennberg, B, Svensson, C, Svane, G. Abnormalities on chest radiographs following radiation therapy for breast cancer. Eur Radiol 2000; 10 (3): 484–489.
13.West, C M, Elliott, R M, Burnet, N G. The genomics revolution and radiotherapy. Clin Oncol (R Coll Radiol) 2007; 19 (6): 470–480.
14.Johansson, S, Bjermer, L, Franzen, L, Henriksson, R. Effects of ongoing smoking on the development of radiation-induced pneumonitis in breast cancer and oesophagus cancer patients. Radiother Oncol 1998; 49 (1): 41–47.
15.Vogelius, I R, Bentzen, S M. A literature-based meta-analysis of clinical risk factors for development of radiation induced pneumonitis. Acta Oncol 2012; 51 (8): 975–983.
16.Lind, P A, Rosfors, S, Wennberg, B, Glas, U, Bevegard, S, Fornander, T. Pulmonary function following adjuvant chemotherapy and radiotherapy for breast cancer and the issue of three-dimensional treatment planning. Radiother Oncol 1998; 49 (3): 245–254.
17.Lehne, G, Lote, K. Pulmonary toxicity of cytotoxic and immunosuppressive agents. A review. Acta Oncol 1990; 29 (2): 113–124.
18.Taghian, A G, Assaad, S I, Niemierko, A, Floyd, S R, Powell, S N. Is a reduction in radiation lung volume and dose necessary with paclitaxel chemotherapy for node-positive breast cancer? Int J Radiat Oncol Biol Phys 2005; 62 (2): 386–391.
19.Theuws, J C, Kwa, S L, Wagenaar, A Cet al. Prediction of overall pulmonary function loss in relation to the 3-D dose distribution for patients with breast cancer and malignant lymphoma. Radiother Oncol 1998; 49 (3): 233–243.
20.Azria, D, Belkacemi, Y, Romieu, Get al. Concurrent or sequential adjuvant letrozole and radiotherapy after conservative surgery for early-stage breast cancer (CO-HO-RT): a phase 2 randomised trial. Lancet Oncol 2010; 11 (3): 258–265.
21.Halyard, M Y, Pisansky, T M, Dueck, A Cet al. Radiotherapy and adjuvant trastuzumab in operable breast cancer: tolerability and adverse event data from the NCCTG Phase III Trial N9831. J Clin Oncol 2009; 27 (16): 2638–2644.
22.Belkacemi, Y, Gligorov, J, Ozsahin, Met al. Concurrent trastuzumab with adjuvant radiotherapy in HER2-positive breast cancer patients: acute toxicity analyses from the French multicentric study. Ann Oncol 2008; 19 (6): 1110–1116.
24.Fontanilla, H P, Woodward, W A, Lindberg, M E, Kanke, J E. Current clinical coverage of Radiation Therapy Oncology Group-defined target volumes for postmastectomy radation therapy. Pract Radiat Oncol 2012; 2 (3): 201–209.
25.Erven, K, Weltens, C, Nackaerts, K, Fieuws, S, Decramer, M, Lievens, Y. Changes in pulmonary function up to 10 years after locoregional breast irradiation. Int J Radiat Oncol Biol Phys 2012; 82 (2): 701–707.
26.Prochazka, M, Granath, F, Ekbom, A, Shields, P G, Hall, P. Lung cancer risks in women with previous breast cancer. Eur J Cancer 2002; 38 (11): 1520–1525.